FLEMINGTON, N.J.--(BUSINESS WIRE)--NovaDel Pharma Inc. (AMEX: NVD) today announced positive results from a pilot pharmacokinetic study comparing its new and improved formulation of Zolpidem Oral Spray to Ambien® tablets. Zolpidem is the active ingredient in Ambien®, Sanofi-Aventis’ leading treatment for insomnia.
